{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.7","upperLimit":"4.8","value":"2.8"},{"groupId":"OG001","lowerLimit":"1.7","upperLimit":"3.4","value":"1.9"},{"groupId":"OG002","lowerLimit":"1.4","upperLimit":"3.8","value":"1.8"},{"groupId":"OG003","lowerLimit":"1.6","upperLimit":"1.9","value":"1.7"},{"groupId":"OG004","lowerLimit":"1.7","upperLimit":"3.6","value":"2.0"},{"groupId":"OG005","lowerLimit":"1.8","upperLimit":"5.5","value":"2.9"},{"groupId":"OG006","lowerLimit":"1.3","upperLimit":"3.4","value":"1.8"},{"groupId":"OG007","lowerLimit":"1.1","upperLimit":"4.9","value":"1.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"30"},{"groupId":"OG003","value":"68"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"30"},{"groupId":"OG006","value":"30"},{"groupId":"OG007","value":"11"}],"units":"Participants"}],"description":"Progression-free survival (PFS) was defined as as the time from the first dose to the first objectively documented disease progression per RECIST v1.1 per Investigator assessment or death due to any cause in the absence of documented progressive disease (PD). PFS was analyzed using Kaplan-Meier methods. Participants who discontinued from the study, did not die or have disease progression, or who received new anticancer therapy were censored on the date of last evaluable assessment prior to initiation of subsequent therapy. Participants with no evaluable baseline or post-baseline assessments were censored on the date of first dose.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with NSCLC with no prior exposure to any PD-1 pathway targeting drug (PD-1 naïve) received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG000","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: NSCLC (PD-1 Naïve)"},{"description":"Participants with NSCLC with de novo or acquired resistance to an anti-PD-1 targeting drug (PD-1 resistant) received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG001","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: NSCLC (PD-1 Resistant)"},{"description":"Participants with SCCHN received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG002","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: SCCHN"},{"description":"Participants with pancreatic cancer received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG003","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: Pancreatic Cancer"},{"description":"Participants with advanced ovarian cancer received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG004","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: Ovarian Cancer"},{"description":"Participants with RCC received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG005","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: RCC"},{"description":"Participants with malignant glioma received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG006","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: GBM"},{"description":"Participants with melanoma received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG007","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: Melanoma"}],"paramType":"MEDIAN","populationDescription":"All treated participants in Phase 1b; Efficacy endpoints were specified to be analyzed by disease type for phase 1b participants only.","reportingStatus":"POSTED","timeFrame":"From first dose of study drug up to the end of study; maximum time on study in phase 1b was 35.9 months.","title":"Efficacy: Progression Free Survival (Phase 1b)","type":"SECONDARY","unitOfMeasure":"months"}